Monitoring hepatitis B reactivation and antiviral side effects in people starting immunosuppressive treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The REANT Cohort is a 4-year prospective, multicenter cohort enrolling adults who are anti-HBc IgG positive and initiating HBV prophylaxis because of planned immunosuppressive therapy. Participants will undergo regular longitudinal assessments of bone mineral density, renal filtration and tubular function, and metabolic profiles, with data captured in a centralized e-CRF. The study will analyze relationships between specific antiviral agents, baseline comorbidities, and subsequent organ dysfunction over time. Each participating center aims to enroll approximately 35 patients with enrollment scheduled to finish by June 30, 2026.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 years or older
* Positive for Anti-HBc IgG
* Must be candidate for immunosuppressive therapy.

Exclusion Criteria:

* Voluntary Withdrawal
* Failure to attend follow-up visits

Where it's running

• Cukurova University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
  Adana, Turkey (Türkiye) Recruiting
• Ankara Gazi University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
  Ankara, Turkey (Türkiye) Recruiting
• Bilkent City Hospital Department of Infectious Diseases and Clinical Microbiology
  Ankara, Turkey (Türkiye) Recruiting
• Akdeniz University, Faculty of Medicine, Department of Infectious Diseases and Clinical Mİcrobiology
  Antalya, Turkey (Türkiye) Recruiting
• Dicle University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
  Diyarbakır, Turkey (Türkiye) Recruiting
• Diyarbakir, Memorial Hospital Department of Infectious Diseases and Clinical Microbiology
  Diyarbakır, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: cigdem Mermutluoglu — Dicle University, Medical Faculty
• Study coordinator: Cigdem Mermutluoglu, MD, Assoc. Prof.
• Email: cigdemmermut@gmail.com
• Phone: +905052252700

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personal health app in young-to-midlife adults in Hong Kong

  This trial tests whether the Wellnuts self-health assessment app helps asymptomatic adults in Hong Kong become more health-aware and proactive about care, compared with standard online health resources.

  Recruiting The University of Hong Kong · Hong Kong · NCT07720245

• Bile acid and gut microbiota changes in people with hepatitis D starting bulevirtide

  This project will see if starting bulevirtide changes bile acids and gut bacteria in adults with chronic hepatitis D who are already on hepatitis B therapy.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07429864

• MagIA H3S multiplex rapid blood test for HIV, hepatitis B and C, and syphilis

  This project will test a single blood-based point-of-care test that checks for HIV, hepatitis B and C, and syphilis using serum or plasma samples from people at sites in Ivory Coast and Kenya.

  Recruiting at 2 sites MagIA Diagnostics · Abidjan and 1 other locations · NCT07170748

• Untreated or Unknown HBV, HDV, and HCV in South-East Austria: See if People Need Care

  This study looks at past test results to see how many people in South-East Austria have hepatitis B, hepatitis D coinfection, or hepatitis C that hasn’t been treated yet or isn’t known, and then invites them for care.

  Recruiting Medical University of Graz · Graz, Styra · NCT06834178

• Treatment for Hepatitis B in individuals with a family history of liver cancer

  This study is testing if a combination treatment of Peginterferon α-2b and other medications can help people with a family history of liver cancer who have chronic Hepatitis B feel better and lower their risk of developing liver cancer.

  Recruiting at 4 sites Xiangya Hospital of Central South University · Guangzhou, Guangdong and 3 other locations · NCT06746701

• Evaluating Tune-401 for safety and effectiveness in adults with Chronic Hepatitis B

  This study is testing a new drug called Tune-401 to see if it is safe and effective for adults with Chronic Hepatitis B.

  Recruiting at 3 sites Phase 1 Tune Therapeutics, Inc. · Hong Kong and 2 other locations · NCT06671093

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.